Asahi Kasei Pharma Corporation (AKP) is a fully integrated Japanese pharmaceutical company with capabilities in R&D, manufacturing and commercialization.

AKP has a well established management team for clinical trials, giving us a strong track records to obtain market approvals for products and an experienced nationwide sales force in Japan.

AKP has successfully partnered with large and small organizations to develop and commercialize a variety of innovative treatments including Famvir, Flivas, Toledomin, Xiaflex, Reclast, Kevzara and Plaquenil as well as our own original products such as Teribone and Recomodulin.

Our focus areas are musculoskeletal disorders including pain management, autoimmune diseases, critical care, hematologic diseases, refractory respiratory diseases and rare diseases.

We are looking for opportunities in the above fields for Japanese market.